ArticleFrontiers in public health2025
The cost-effectiveness analysis of single-tablet efavirenz-based regimen among HIV-1 infected adults in China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advancing Precision Public Health: an implementation science framework for HIV Cluster Detection and Response driven by molecular epidemiology.Frontiers in public health · 2026Article
- Acceptance and preference for long-acting antiretrovirals among people living with HIV in China.BMC public health · 2025Article
- Pharmacoeconomic perspectives on HIV: integrating data for long-term treatment and prevention.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In 2018, the Chinese Guidelines for Diagnosis and Treatment of HIV/AIDS recommended the adoption of the efavirenz 400 mg-based TLE (tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV)) regimen as the primary first-line treatment for ART-naive HIV-1 infected adults in China. However, the cost-effectiveness of different TLE treatment strategies remains uncertain. This study aimed to evaluate the cost-effectiveness of various TLE treatment strategies for ART-naive HIV-1 infected adults in China. Methods: A decision-tree Markov state transition model was employed to assess the cost-effectiveness of various TLE treatment strategies over a 10-year timeframe, from a societal perspective. Input parameters were obtained from published literature and publicly accessible information. Local data from the latest sources were used as input parameters whenever possible. The main outcome measure was the incremental costs per quality-adjusted life years (QALYs) gained. Sensitivity analyses were performed to investigate model uncertainties and determine break-even prices. Results: Compared to the multiple-tablet regimen (MTR) consisting of efavirenz 400 mg-based TLE (TLE400) and efavirenz 600 mg-based TLE (TLE600), the single-tablet regimen (STR) of TLE400 exhibited a 10-year cost of 130733.8 CNY (compared to 122939.7 CNY and 126184.3 CNY, respectively) and an expected QALYs of 6.45 (compared to 6.27 QALYs and 6.32 QALYs, respectively) per HIV-1 patient in China. Consequently, the incremental cost-effectiveness ratios (ICERs) were 41021.6 CNY/QALY gained (equivalent to US$ 6071.2 per QALY gained) and 34996.2 CNY/QALY gained (equivalent to US$ 5179.4 per QALY gained) for TLE400 STR compared to TLE400 MTR and TLE600 MTR, respectively. The ICER for TLE400 MTR compared to TLE600 MTR was 54076.7 CNY/QALY gained (equivalent to US$ 8003.4 per QALY gained). Deterministic sensitivity analysis indicated that adherence rates to ART had the most significant influence on all three strategies. In probabilistic sensitivity analysis, TLE400 STR demonstrated a 71.4% probability of being highly cost-effective nationwide, based on the one-time national-level GDP per capita. Conclusion: In the context of treating HIV-1 infected adults in China, the STR of TLE400 demonstrated cost-effectiveness when compared to both the MTR of TLE400 and the MTR of TLE600.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.